ATLANTA, GEORGIA, March 4, 2021 – New Realm Brewing Company is excited to announce the opening of a distillery in the heart of Savannah’s Historic District in the Spring of 2021. The 12,000 square foot, three-story facility is located at 120 Whitaker Street and will feature a distillery, brewery, restaurant, tasting room, rooftop patio and dedicated private event spaces.

In 2019, New Realm began making London Dry Gin, Tennessee Style Bourbon, and Gluten-Free Vodka, which New Realm has been selling on-site in the Company’s flagship Atlanta location.

“Over the past year we have seen tremendous demand for our spirits and craft cocktail offerings in Atlanta and are excited to open a new facility dedicated to creating best-in-class distilled products. The Savannah distillery will allow New Realm to expand and improve its distilled product offering, increase innovation, and provide additional opportunities for our customers to experience New Realm’s hand-crafted beers brewed by renowned brewmaster Mitch Steele,” said Carey Falcone, Co-Founder and CEO of New Realm.

New Realm’s new craft distillery and restaurant is expected to add approximately 100 full-time employees in the local Savannah market. New Realm is focused on positively impacting the communities in which it operates, and maintains a firm commitment to environmental sustainability, supporting local, independent craft communities and the art and science of great craft brewing and distilling.

The Savannah distillery and restaurant will be New Realm’s third location alongside their flagship brewery and restaurant in Atlanta, Georgia (550 Somerset Terrace NE in Atlanta, Georgia) and production brewery and restaurant in Virginia Beach, Virginia (1209 Craft Lane in Virginia Beach, Virginia).

New Realm products are currently available at its locations in Atlanta and Virginia Beach, as well as at bars and retail locations throughout Georgia and Virginia. For a complete list of hours, information on private events and public tours, as well as additional information, visit newrealmbrewing.com.

Funding Will Accelerate FDA Submission and Commercialization of Automated Benchtop Blood Testing System

TYH Ventures, Glen Tullman of 7WireVentures, and Wittington Ventures Led the Round, Joined by General Catalyst, GreatPoint Ventures, DNS Capital, and Wasson Enterprise

Prominent Industry Leaders Join Executive Team and Board of Directors

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ — Truvian Sciences (“Truvian”) today announced the close of more than $105 million in an oversubscribed Series C financing round led by TYH Ventures, Glen Tullman of 7wireVentures, and Wittington Ventures. The funds will advance development of Truvian’s automated benchtop blood testing system, paving the way to submit the device for U.S. Food and Drug Administration (FDA) clearance, and enabling the company to scale its team in preparation for broad commercialization. Inclusive of the Series C, Truvian has raised more than $150 million in funding to date.

“The global pandemic has further demonstrated that consumers want more control over their personal healthcare journeys. Today’s announcement signifies tremendous confidence in Truvian’s goal of decentralizing healthcare by bringing point-of-care diagnostic testing to a highly complex, distributed market,” said Jeff Hawkins, President and Chief Executive Officer of Truvian. “I have full confidence that our executive team and board have the proven leadership and depth of experience in healthcare to deliver our benchtop platform and test menu through global regulatory approvals, making routine testing more convenient and accessible for all.”

Expanded Leadership Team Positions Company for Long-Term Growth and Innovation

The company also announced an impressive roster of executive and board appointments. Former Divisional VP of Automation and Informatics at Abbott, Jay Srinivasan, has joined the company as Chief Product Officer. Several new investors will join the Board of Directors, including Glen Tullman, Managing Partner of 7wireVentures, Founder and former Executive Chairman and CEO of Livongo Health, and former CEO of both Allscripts and Enterprise Systems; Greg Wasson, President and Co-Founder of Wasson Enterprise and former President and CEO of Walgreens Boots Alliance; and Megh Gupta, Partner at Wittington Ventures and former Global Head of Strategy and Corporate Development at Element AI. Renowned inventor Dean Kamen, known for his work in developing numerous medical devices including drug infusion pumps, portable dialysis machines, insulin pumps, and prosthetic arms, has been named to the position of Senior Technology Advisor.

“Truvian has persevered through the challenges of the global pandemic this year and emerged stronger with a laser focus on commercializing their core point-of-care blood testing solutions with a clear plan to achieve success and thus democratize routine diagnostics,” said Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures. “GreatPoint Ventures looks forward to continuing our work with Truvian.”

“As we move to a more consumer-directed system of healthcare, providing easy, convenient access to a full suite of high-quality blood tests at a local pharmacy, an on-site clinic at work or a physician office will be a game changer,” said Glen Tullman, Managing Partner at 7wireVentures, who co-led the round and formed a new entity for special investments outside of the core holdings of 7wireVentures, the successful early stage healthcare fund formed by Tullman and long-time business partner Lee Shapiro. He continued, “New rapid diagnostic tools are essential to provide health consumers with more information earlier in the process and equip clinicians with the information they need to provide high-quality care.”

Truvian Products in Development

Truvian’s approach to improving healthcare testing is based on developing a compact and fully automated benchtop system that combines chemistries, immunoassays, and hematology assays in one device. There is no other single on-site diagnostic platform that covers the breadth of analytes that Truvian can address, with accuracy that rivals central labs. By combining multiple testing modalities into one system, clinics can perform all standard blood tests ordered during a routine check-up on-site, helping their patients realize significant cost and time savings. Truvian’s comprehensive wellness panel will cover the most commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count.

About Truvian Sciences

Truvian is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system is being developed to produce lab-accurate results for a full-suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian’s system delivers a convenient and affordable alternative to off-site labs, providing immediate insights to inform healthcare decisions. Truvian was founded by individuals with deep domain experience in healthcare, diagnostics, and consumer technology. Today, the team has expanded to include top scientists, engineers, and healthcare business leaders — each bringing specialized expertise to drive Truvian’s mission of making routine health testing convenient, affordable, and actionable. For more information, visit www.truvianhealth.com.

SOURCE Truvian Sciences

Related Links
www.truvianhealth.com

Mayfield Fund, Continental, Robert Bosch Venture Capital, and Existing Investors Join WRVI Capital in Financing Developer of Highest-Performing Power-Efficient Perception Processing Technologies for Autonomous Vehicles

SAN JOSE, Calif. and MUNICH, Feb. 17, 2021 /PRNewswire/ — Recogni Inc., the developers of an AI vision cognition system for autonomous vehicles, today announced $48.9 million in a Series B financing round, led by WRVI Capital, a prominent global technology investor. The proceeds will help Recogni bring its perception platform to market and expand its engineering and go-to-market teams.

In addition to WRVI Capital, new investors Mayfield Fund, Continental, and Robert Bosch Venture Capital joined existing investors GreatPoint Ventures, Toyota AI Ventures, BMW i Ventures, Fluxunit – OSRAM Ventures, and DNS Capital in the current financing round.

Recogni’s AI-powered vision cognition module (VCM) will address the challenges of autonomous vehicle design and deployment. Applying innovations in artificial intelligence, application-specific integrated circuits (ASICs), and system software, the VCM will deliver groundbreaking performance at ultra-low power consumption, enabling high-resolution and high-frame-rate image processing from multiple cameras concurrently in real time.

“As Silicon Valley-based deep technology investors, we understand the impact that fundamental breakthroughs in silicon architecture, embedded software, AI algorithms, and power efficiency can have on autonomous vehicle development,” said Sriram Viswanathan, Founding Managing Partner of WRVI Capital. “We were attracted to Recogni’s team, the innovations across multiple domains, and the potential to massively accelerate the journey to fully autonomous transportation. We are convinced their innovations have the potential to make them the leader in this market segment.”

“This investment is a strong endorsement of Recogni’s vision from venture and industry leaders. We are moving along our journey of solving the challenge of perception processing and power efficiency, by building the world’s highest-performing AI inference system at the lowest energy consumption,” said R K Anand, Recogni’s Chief Executive Officer.

“As a people-first investor, it always begins with the team,” said Navin Chaddha, Managing Director, Mayfield. “I first met R K seven years ago. I have always been impressed by him and we have kept in touch since then. When you combine that with our belief in the renaissance of silicon, it was obvious that Recogni’s approach to AI edge inference will help develop new generations of safe, power-efficient, self-driving vehicles. We look forward to partnering with them as they help put silicon back into Silicon Valley.”

Tier 1 suppliers have continuously strengthened their AD technology expertise for years. “Continental has a strong focus on developing automated and autonomous vehicle technologies. Therefore, investing in Recogni perfectly supports our high-performance computing strategy for autonomous vehicle functions,” said Rouven Spinner, Investment Partner at Continental. “Our shared focus and complementary expertise enable us to see the value of Recogni’s vision cognition technology. We are excited to work with the Recogni team on next-generation perception technologies.”

“RBVC invests in innovative startups that can change the course of an emerging market,” said Luis Llovera, Managing Director at Robert Bosch Venture Capital. “The outstanding performance of Recogni’s solution convinced us to invest. Their AI-powered vision platform will enable Tier 1s and OEMs to accelerate the transition from just safety features to full autonomy.”

“As the first investor in Recogni, we are thrilled to welcome WRVI, Mayfield, Continental, and RBVC to the Recogni family and together with our participation in this round it validates our conviction that the vision of safe, energy-efficient autonomous Level-4 and Level-5 vehicles is coming to fruition,” said Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures.

About Recogni

Recogni’s mission is to design a vison-oriented artificial intelligence system from the ground up. The systems will deliver unprecedented performance through novel edge AI processing, allowing vehicles to see farther and faster and make driving decisions more accurately than humans while consuming minimal amounts of energy. The company is headquartered in San Jose, Calif. and has operations in Munich, Germany. For more information, visit www.recogni.com.

About WRVI Capital

WRVI Capital is a leading venture capital firm that invests in exceptional entrepreneurs and disruptive technologies that will help shape the future. The management team and investment professionals leverage over 400 years of accumulated investment and operational experience and bring to the portfolio companies a deep and unmatched network of value-added strategic relationships. WRVI Capital invests globally and has offices in California, Israel, and India. For more information, visit www.wrvi.vc

About Mayfield

Mayfield is a venture capital firm with a people-first philosophy and $2.5 billion under management. Mayfield invests primarily in early-stage consumer, enterprise and engineering biology companies. Since its founding 50 years ago, the firm has invested in more than 500 companies, resulting in 118 IPOs and more than 200 acquisitions. For more information, go to www.mayfield.com or follow @MayfieldFund.

About Continental

Continental develops pioneering technologies and services for sustainable and connected mobility of people and their goods. Founded in 1871, the technology company offers safe, efficient, intelligent, and affordable solutions for vehicles, machines, traffic and transportation. In 2019, Continental generated sales of €44.5 billion and currently employs more than 233,000 people in 59 countries and markets. In 2021, the company celebrates its 150th anniversary. www.continental.com

About RBVC GmbH

Robert Bosch Venture Capital GmbH (RBVC) is the corporate venture capital company of the Bosch Group, a leading global supplier of technology and services. RBVC invests worldwide in innovative start-up companies at all stages of their development. Its investment activities focus on technology companies working in areas of business of current and future relevance for Bosch, above all, automation and electrification, energy efficiency, enabling technologies, and healthcare systems. RBVC also invests in services and business models that are relevant to the above-mentioned areas of business. Additional information is available at: www.rbvc.com.

Contact:

Manish Singh
VP Marketing
Recogni
manish@recogni.com
+1 408 802 1470

SOURCE Recogni

Latest Paw release integrates with the RapidAPI platform, expands support beyond Mac to include Windows, Linux, and web versionsd growth as API-first digital transformation becomes a top initiative across all industries

SAN FRANCISCO–(BUSINESS WIRE)–RapidAPI, a next-generation API Platform that enables developers and enterprises to find, connect to, and manage thousands of APIs, announced today the acquisition of Paw, a leading API design and collaboration tool. The acquisition enables RapidAPI to extend its open API platform across the entire API development lifecycle, creating a connected experience for developers from API development to consumption, across multiple clouds and gateways.

“Paw has gained traction over the last six years by building an API design tool that was beloved by Mac users for its strong UI and performance.”

Additionally, RapidAPI and Paw announced the first successful collaboration between the two companies – Paw will now support Windows and Linux in addition to Mac. This latest release brings the intuitive UI, advanced features, and superior performance that tens of thousands of Mac users have come to rely on with Paw, to an even broader audience. With Paw, users can simplify development workflows and streamline API collaboration, enabling organizations to accelerate API delivery and improve the developer experience.

“As digital transformation efforts have accelerated over the last year, so has the demand for the modern API tooling that developers require to build digital services and business models,” said Iddo Gino, RapidAPI founder and CEO. “Although there has been a surge in the number of API products and services on the market over the last year, RapidAPI is one of the few that is truly built with the developer in mind.”

Added Gino, “With the addition of Paw, we will offer developers a unified experience from designing and developing APIs with Paw, to testing and monitoring them with RapidAPI Testing, to sharing and managing them on the RapidAPI marketplace. And to ensure that Paw is more widely available beyond its loyal Mac users, we’ve been working together to implement support for Web, Windows, and Linux versions.”

Fully-Featured for Mac, Windows, and Linux

As part of the RapidAPI platform, Paw provides a fully-featured API client that supports complex design and development workflows with intuitive UX, cross-platform collaboration, and integration with RapidAPI Marketplace and RapidAPI Enterprise Hub. It supports any type of web API, with an emphasis on REST and GraphQL APIs. With Paw, developers can:

  • Improve Developer Experience: Paw has an intuitive UX and provides superior performance, providing users with a better developer experience. With Paw, users can quickly create, find, and run API requests with an intuitive top-level sidebar navigation and a simple interface for setting up arguments, headers, and parameters.
  • Accelerate API Delivery: Paw eases design and development workflows for ongoing API projects by offering powerful environment variables and dynamic values that improve productivity for developers. Unlike other design solutions, Paw can be extended through its JavaScript API to allow custom API flows.
  • Collaborate Across Teams: Paw enables multiple development teams to collaborate while keeping all API calls in sync, increase productivity for all team members involved in designing and consuming APIs, including product managers designing the API structure, backend developers implementing the API, QA engineers testing the API, and frontend developers consuming the API.

“Paw has gained traction over the last six years by building an API design tool that was beloved by Mac users for its strong UI and performance,” said Micha Mizaheri, founder and CEO of Paw. “By joining forces with RapidAPI, we are able to take that developer experience to the next level by making Paw available across multiple platforms and integrating it across RapidAPI’s domain of developer tools. I’m thrilled to share the same vision as Iddo of creating products where the developer experience is always prioritized.”

The latest release with cross platform support is currently in beta and is free for individual users. Sign-up to be part of the Paw trial.

For more information

About RapidAPI

RapidAPI, the world’s largest API Marketplace, is used by millions of developers to find, test and connect to thousands of APIs—all with a single account, API key and SDK. For enterprise organizations, RapidAPI offers RapidAPI Enterprise Hub, a white-labeled version of the marketplace that enables the company’s developers, customers, and partners to find, manage, and connect to hundreds of internal APIs, as well as external API subscriptions.

About Paw

Paw is a full-featured API design tool for API design, discovery, and collaboration. Widely recognized for its time-saving UX, extensibility, and performance, Paw has been the number one choice among Mac developers for the last five years. Paw enables you to visually build your API requests and describe each parameter through textual descriptions, typing, and constraints. Founded in 2014, Paw was privately funded until its acquisition by RapidAPI at the end of 2020.

Contacts
Josh Purdy
josh@bospar.com
(612) 695-0168

WEST CHESTER, OHIO, 02/09/2021 – Lithko Contracting, LLC (“Lithko”), a leading national concrete contractor, along with their equity partners The Pritzker Organization and DNS Capital, announced today that on December 31, 2020 they acquired assets of Pikus Concrete & Construction, LLC (Pikus).

Pikus is a nationally recognized commercial and industrial concrete contractor serving Salt Lake and the Wasatch Valley market since 1999. They specialize in cast-in-place concrete including post-tensioned decks, multi-story commercial structures, and parking structures. Pikus has approximately 200 coworkers serving a customer base of large nationally recognized general contractors in Utah and the surrounding region.

Lithko is a market-leading, full service commercial concrete contractor specializing in the execution of walls, tilt-ups structural frames, slabs, super flats, site work, foundations and pre-construction services. Lithko has over 3,000 coworkers serving over 500 clients across 19 geographic regions. Lithko has a unique local service model designed to keep co-workers close to home and create exceptional customer service in each town.

Rob Pikus, Pikus President, said, “The team at Pikus is excited to partner with Lithko. Our new partnership will drive exceptional value and solidify our place as an industry leader in Utah and the Wasatch Valley. Our excitement extends to our coworkers, customers and vendor partners.”

Rob Strobel, Lithko President, said, “Pikus has a dedicated team of accomplished individuals with extensive industry experience. We are excited to have a presence in Salt Lake City and the Wasatch Valley market, which is known as “Silicon Slopes”, a growing technology region. We look forward to working closely with Rob and the Pikus team to help them build on their impressive track record of success.”

Capstone Headwaters acted as financial advisor for Pikus.

Contacts:
Lithko Contracting, LLC
Kristin Nordyke
(614) 733-0300
nordykek@lithko.com
www.lithko.com

Biological sensors developed by MIT spinout Glympse Bio could help clinicians make decisions for individual patients.

Zach Winn | MIT News Office

In the fight against severe diseases like cancer, patients often endure a discomforting, weekslong gap between when treatment begins and when doctors can tell if it’s working. The problem often stems from an inability to track the disease’s progression in anything close to real time.

Now Glympse Bio, a startup spun out of the lab of Sangeeta Bhatia, the John J. and Dorothy Wilson Professor of Electrical Engineering and Computer Science at MIT and director of the Marble Center for Cancer Nanomedicine, is working to shine a light on disease activity using synthetic biosensors. After being injected into the body, the sensors travel to the disease site and measure protein changes associated with that disease. The sensors are then excreted in urine and analyzed using standard laboratory techniques.

The company believes its technology holds potential to transform disease detection and tracking. By providing clinicians with current, data-driven insights, it could also improve the treatment of disease.

“When a patient is put on a medicine, it’s really a waiting game,” says Bhatia, Glympse Bio co-founder who is also a member of MIT’s Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science. “There’s often nothing to do but wait to see if a disease is responding. We hope this technology can provide information to clinicians and patients earlier.”

Glympse recently completed a Phase 1 trial of its sensors in patients with non-alcoholic steatohepatitis (NASH), a potentially deadly liver disease estimated to affect about 12 percent of adults in the U.S. Because the current process for diagnosing NASH involves sampling a piece of the liver through a biopsy, it often remains undetected until the disease is in its most advanced stages.

Glympse is also tuning its sensors to track the progression of certain cancers, infections, and inflammation. Success in those fields would give drug development companies, doctors, and patients a potent new tool in the fight against an array of life-threatening diseases.

“With this platform you open up several different universes,” Glympse CEO Caroline Loew says. “For diseases that are harder to diagnose, you get to diagnose them faster, you get to be able to develop drugs for them more effectively, and you get to treat them faster.”

Sensing an opportunity

Like many great scientific advances, the discovery that led to Glympse was serendipitous. Around 2008, Bhatia’s group was using tagged magnetic particles that travel to tumors in the body, where they could reveal their location through an MRI scan. In every cancer experiment, the researchers noticed the bladder lit up with the tag.

“We realized we didn’t need an imaging machine anymore, we could just give a shot and do a urine test,” Bhatia says.

By 2012, Glympse co-founder Gabe Kwong, a postdoc in Bhatia’s lab between 2009 and 2014, had developed the tagging technology enough to map changes in protein activity to the progression of multiple diseases. Some of that early work was funded, in part, by the Koch Institute Frontier Research Program.

After some encouragement from her colleagues, Bhatia assembled a team of advisors including Institute Professor Robert Langer and secured a grant from MIT’s Deshpande Center to start the company. Bhatia eventually took a sabbatical from MIT to help the company identify its first target, NASH, raise venture capital, secure a partnership with the pharmaceutical company Gilead Sciences, and understand how the sensors would be regulated by the Food and Drug Administration.

The progress was enough to attract Loew, who had spent her career helping large pharmaceutical companies develop drugs. Loew says she was impressed by the breadth of insights Glympse could glean with its biosensor platform, which measures the activity of enzymes called proteases that are altered in a variety of serious diseases.

Loew led the company as its focus has broadened from diagnostics to precise disease tracking during treatment.

“We began thinking about earlier cancer detection because you can save a lot of lives by finding cancer early,” Bhatia says. “Now we’re realizing that we can potentially understand whether new drugs are working and if the patients are on the right medicine.”

The company believes it can understand not just if a specific drug is working but how it is working through protease data.

“We can help determine whether the drug is activating at a site of engagement, we can tell mechanisms of action because there’s specific protease activity that’s associated with that, we can determine through a course of treatment whether the disease is increasing or decreasing, we can track all that through a protease signature,” Loew says.

A platform with potential

Through its partnership with Gilead, Glympse’s technology is expected to move into efficacy trials with NASH patients later this year. The company hopes those trials show the power of its approach for gathering previously unattainable data.

Those insights could also transform treatment. Looking forward, Glympse hopes to help clinicians make care decisions for patients based on both real-time disease response and how the disease has responded in similar patients at similar stages of treatment.

That would represent a paradigm shift in areas like cancer immunotherapy, in which doctors often must make do with little information for months after treatment begins.

“Many of these patients have very fast advancing cancers,” Loew says. “To get the patients quickly stratified to the right treatment is critically important. Days mean everything to these patients, and sometimes we see patients waiting around for nine to 12 weeks to see if they’re having a response to these drugs. In our preclinical data, we’re determining if there’s a response in a week or two. If we’re able to pull that through, it’s game-changing.”

WEST CHESTER, OHIO, January 15, 2021 – Lithko Contracting, LLC (“Lithko”), a leading national concrete contractor, along with their equity partners The Pritzker Organization and DNS Capital, announced today that on December 31, 2020 they acquired assets of Capitol Concrete Contractors, Inc. (Capitol).

Capitol has been providing superior concrete contracting services since 2003, specializing in total package concrete construction, including foundations, tilt-walls, slabs, and site work. Capitol has over 300 coworkers, serving clients across the Austin and Central Texas regions. Capital has a focus on family values and loyalty to their coworkers while creating and maintaining strong customer relationships based on dependability, quality, and safety.

Lithko is a market-leading, full service commercial concrete contractor specializing in the execution of walls, tilt-ups structural frames, slabs, super flats, site work, foundations and pre-construction services. Lithko has over 3,000 coworkers serving over 500 clients across 19 geographic regions. Lithko has a unique local service model designed to keep co-workers close to home and create exceptional customer service in each town.

Jordan Moore, Capitol Vice President, said, “The team at Capitol is excited to partner with Lithko. Our new partnership will drive exceptional value and solidify our place as an industry leader in the Austin and Central Texas Region. Our excitement extends to our coworkers, customers and vendor partners.”

Rob Strobel, Lithko President, said, “Capitol has an exceptional team and a proven track record of delivering value to its customers. We are delighted to have a presence in the Austin market and support the growth of the business over the long term. We look forward to working closely with Jordan and the Capitol team to help them build on their impressive track record of success.”

Morrison, Friedrich & Spinn, CPAs acted as financial advisor and Axiom was the broker for Capitol. D.A. Davidson & Co. was broker for Lithko.

Contacts:
Lithko Contracting, LLC
Kristin Nordyke
(614) 733-0300
nordykek@lithko.com
www.lithko.com

Glympse Bio Announces $46.7 Million Series B Financing
Proceeds Support PMA-Enabling Study of Glympse Technology in NASH Patients

CAMBRIDGE, Mass., July 15, 2020 – Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and
infectious diseases.

The financing round was led by Section 32 and includes new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, as well as existing investors, including LS Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint Ventures, Gilead Sciences, and others also participated. In connection with the financing, Steven Kafka, Ph.D., Managing Partner at Section 32, and George Zachary, General Partner at CRV, will join the Glympse Board of Directors. Cayce Denton, Director at Temasek, and Andrew Perlman, Managing Partner at GreatPoint Ventures, will join the Board as Observers.

“The confidence and commitment from our new and existing investors further reinforces Glympse’s vision to improve the way diseases are understood, treatments are developed, healthcare is delivered, and patients are restored to health,” said Caroline J. Loew, Ph.D., President and Chief Executive Officer of Glympse. “Glympse will advance into PMA-enabling studies in NASH and explore the potential of the platform across multiple other diseases, such as oncology and infectious diseases. The addition of our new board members and expansion of our clinical advisory board will help to guide Glympse as we enhance our understanding of diseases, improve disease detection, and predict treatment response.”

Dr. Kafka added, “The Glympse platform is an exciting new approach to enhance our understanding of and to positively impact human disease. The executive team has executed on its vision with focus, collaboration, and innovation. I look forward to contributing to Glympse’s future growth and success as the company executes on its clinical development plans across multiple diseases and expands its reach with new BioPharma collaborations.”

The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in Non-Alcoholic Steatohepatitis (NASH), a disease that impacts 16 million people in the U.S. and 100 million worldwide. The bioengineered, tunable sensors will be used to determine clinical trial participants’ stage of disease at initial screening and to determine response to study treatment in PMAenabling NASH studies. The biosensors avoid the difficulties seen with needle liver biopsy by providing a safe, repeatable, noninvasive measure of disease activity directly at the liver, thereby potentially predicting the stage of NASH in a patient long before histopathology changes become visible and enabling serial monitoring of treatment progress. Glympse completed first-in-human studies with their NASH product earlier this year. In addition to the NASH pivotal studies, the Series B funding will support further development of the company’s oncology program and initiate development of the infectious disease program.

Wendy Winckler, Ph.D., Chief Scientific Officer, added, “We have engineered tunable and specific biosensors to better understand complex diseases such as fibrosis, cancer, infections, and inflammation. Using a novel noninvasive approach, we can measure real-time biological signals that translate into clinically actionable results. We are paving the way to improve the continuum of care for NASH and build a comprehensive understanding of the disease trajectory that doesn’t currently exist. In oncology, we can directly track tumor progression at the site of disease and measure its response to treatment across a broad range of immunotherapies, targeted therapies, and other standards-of-care. This funding enables us to continue the development of our current programs and expand the application of our
platform into new therapeutic indications.”

Additionally, Glympse strengthens its Clinical Advisory Board with the addition of Padmanee Sharma, M.D., Ph.D., Professor of Genitourinary Medical Oncology and Immunology in the Division of Cancer Medicine at MD Anderson Cancer Center, and Scott Joseph Antonia, M.D., Ph.D., Professor of Medicine and Director of the DCI Center for Cancer Immunotherapy at Duke Cancer Center.

About Glympse Bio
Glympse Bio is focused on better understanding diseases to transform disease detection and predict treatment response. Glympse is transforming the measurement of disease progression in vivo using bioengineered, tunable sensors that are designed for each protease-mediated disease. In October 2019, Glympse announced a strategic collaboration with Gilead Sciences to evaluate Glympse’s technology as both a diagnostic and prognostic tool. Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia. Glympse is headquartered in Cambridge, Mass. For more information, please visit www.glympsebio.com.

Media Contact
Maggie Beller
Russo Partners, LLC
Maggie.beller@russopartnersllc.com
646-942-5631